HongKong:1873

Viva Biotech Successfully Held The 3rd Annual Partnership Summit

SHANGHAI, June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partnership Summit was successfully held. Over 300 attendees joined the Summit, including founders from portfolio companies, representatives from global investment institutions, R&D heads from pharmaceu...

2022-06-23 20:30 1482

Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron

SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio companies have had great progress. Anji Pharma Complete...

2022-05-26 23:53 2377

Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%

Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...

2022-03-29 01:01 1928

Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%

Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...

2022-03-29 00:49 1867

Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests

SHANGHAI, March 18, 2022 /PRNewswire/ -- At present, COVID-19 is still in pandemic status around the world. The superposition of Delta and Omicron variants are rampant, resulting in the continuous enhancement of their transmission ability. Amid the repeated waves of COVID-19, in addition to COVI...

2022-03-18 17:47 1037

Viva Biotech Announced 2021 Interim Results

Revenue Increased by 419.5% YoY, CRO Business Income Increased by 62.5% YoY, O rderBacklog Recorded a Significant Increase of 72% Financial Highlights for the 6 months ended June 30, 2021: * Revenue amounted to RMB1,026.5 million, representing a year-on-year (YoY) increase of approximately 419...

2021-08-31 01:32 4207

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

SHANGHAI, June 15, 2021 /PRNewswire/ -- Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. Totient is a biotech company, harnessing human ...

2021-06-16 10:14 21759

Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology

SHANGHAI, May 10, 2021 /PRNewswire/ -- Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with biotech and IT industry partners to create a multi-party integrated industrial ecosystem, and realiz...

2021-05-10 18:21 1706

Viva Biotech Announced 2020 Annual Results

The Group's Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion Financial Highlights of the year ended December 31, 2020: * Reve...

2021-03-31 07:03 2525

Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders

SHANGHAI, March 10, 2021 /PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leader...

2021-03-10 20:18 5927

Viva Biotech Announced 2020 Interim Results

Financial Highlights for the 6 months ended June 30, 2020 * Revenue amounted to RMB197.6 million, representing a YOY increase of 38.9% * Gross profit amounted to RMB100.1 million, representing a YOY increase of 39.2%, with Gross profit margin of 50.7% * Adjusted net profit rose to RMB123.7 m...

2020-08-31 23:27 5707

Viva Biotech and Schrödinger Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based drug discovery by generatingde novo crystal structures of high-value targets. Under the terms ...

2020-07-29 07:00 10404

Viva Biotech Announced 2019 Annual Results

Financial Highlights For the year ended December 31, 2019 * Revenue amounted to approximately RMB323.1 million, representing a significant YOY increase of 53.9% from approximatelyRMB210.0 million in the same period last year. * Gross profit amounted to approximately RMB155.9 million, represe...

2020-03-31 11:45 2808

Viva Biotech Announces 2019 Interim Results

Financial Highlights * Revenue grew significantly by 83.9% YoY from RMB77.4 million to approximatelyRMB142.3 million. * Gross profit recorded approximately RMB71.9 million, growing significantly by 70.0% fromRMB42.3 million. * Net profit excluding extraordinary profit or loss increased sig...

2019-08-29 11:12 5526